Have you or your loved ones been diagnosed with community-acquired pneumonia, influenza, covid-19?

You may be eligible to participate in a community-acquired pneumonia, influenza, covid-19 clinical trial.

Have you or your loved ones been diagnosed with community-acquired pneumonia, influenza, covid-19? You may be eligible to participate in a community-acquired pneumonia, influenza, covid-19 clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Community-acquired Pneumonia, Influenza, COVID-19 Clinical Trial
NCT02735707 | Phase 3 | Interventional
UMC Utrecht
Sponsored by
UMC Utrecht

Have you or your loved ones been diagnosed with community-acquired pneumonia, influenza, covid-19?

You may be eligible to participate in a community-acquired pneumonia, influenza, covid-19 clinical trial.

Have you or your loved ones been diagnosed with community-acquired pneumonia, influenza, covid-19? You may be eligible to participate in a community-acquired pneumonia, influenza, covid-19 clinical trial.

Recruiting

Male & Female

18 Years +

This study is looking to recruit 10000 Participants

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.